Cover About us Financial highlights To our shareholders Can one company make a difference? Yes, we can...    Helping people with diabetes    Improving global health    Speeding diagnosis of infections    Enhancing pharmaceutical therapies Pursuing our corporate purpose    Community involvement    Volunteerism    Environmental responsibility    Honoring a legacy Enterprise Profile:    BD Medical    BD Diagnostics    BD Biosciences Financials    Financial Review    Financial Statements    Notes to Consolidated Financial Statements    Quarterly Data (unaudited) Performance Comparison Corporate Information Corporate Officers Board of Directors Back Cover

Community involvement Photos, including lower right insert cover, courtesy of the American Red Cross For too many of the world’s children, measles remains a deadly threat Since the development of a vaccine against measles more than 40 years ago, BD syringes have delivered more measles vaccine than those from any other company. While many regions of the world hardly remember this often fatal disease, it still claims the lives of more than 400,000 children annually.      To help relegate measles to history in Africa and Asia, BD has joined with the American Red Cross in the Measles Initiative–a partnership seeking to reduce measles deaths globally by 90 percent between 2000 and 2010.      BD has been a supporter of the Measles Initiative since its launch in 2001. Last year, the Company announced that it would expand its philanthropic support with an additional $1.7 million that includes cash contributions, product donations, safe-injection training, waste management assistance, public relations and advertising, and a youth intern program. The cash portion, totaling $300,000, will help pay for costs associated with the vaccination campaigns.      The Initiative is having a measurable impact. Largely due to technical and financial support provided by the Initiative and the commitment of African governments, more than 217 million of the continent’s children have been vaccinated against measles, saving an estimated 1.2 million lives. Globally, measles deaths have dropped by 48 percent in five years. Photos courtesy of Project HOPE and the U.S. Navy BD is onboard as Project HOPE sets sail once again The SS HOPE, the world’s first peacetime hospital ship, has symbolized Project HOPE since the organization’s founding in 1958. BD has been a partner to Project HOPE since 1970, providing cash, grants, donated products and the energy and expertise of our associates. The HOPE last sailed in 1972, and Project HOPE focused on land-based programs.      After the tsunami that struck southern and southeastern Asia in December 2004, Project HOPE returned to its original maritime calling, collaborating with the U.S. Navy to aid the region through a voyage of the USNS Mercy hospital ship–again, BD was a partner. Based on the success of that mission, this year Project HOPE and the Navy deployed the Mercy to the Philippines, Indonesia, Bangladesh and East Timor. Volunteer doctors and nurses and Navy personnel immunized nearly 11,000 people against malaria, hepatitis A and B, typhus, mumps/ measles/rubella and other diseases. The vaccines were delivered by donated products including BD SoloShot auto-disable syringes, BD Luer-Lok syringes with PrecisionGlide needle and hypodermic needles. BD also donated sharps disposal units.      Since 1987, BD has donated over $12 million in medical supplies to Project HOPE for emergency and programmatic needs, including a $100,000 donation to help in the development of the Basrah Children’s Hospital in Iraq to address the needs of seriously ill and injured children.